Leading experts from industry, academia, and government came together the second week of April in Bethesda, MD, to discuss innovation in the development of an artificial pancreas system at a workshop hosted by the National Institutes of Health, the Food and Drug Administration (FDA), and JDRF. A commercially-viable artificial pancreas system would mimic the biological [...]
“How is managing diabetes like navigating an airplane?” That may sound like the beginning of a bad joke, but the answer resulted in a promising innovation in T1D treatment in JDRF’s current research portfolio. Like many other parents of children with type 1 diabetes (T1D), Don Matheson is well versed in the latest research advances [...]
A first-of-its-kind clinical pilot study has demonstrated the safety and feasibility of an artificial pancreas system in an outpatient, “real-world” setting. A second clinical study has shown that a hypoglycemia-hyperglycemia minimizer system can predict when blood-glucose levels are about to rise or fall and make appropriate adjustments in insulin delivery. These JDRF-supported studies represent critical steps on the path to a functional artificial pancreas for the benefit of people living with T1D.
Over its nearly 40-year history, JDRF has funded more than $1.3 billion toward a cure, accelerating science to the point where we are now funding more than 40 human clinical trials. For people with type 1 diabetes, getting information about trials, and making a decision to enroll in one, is difficult, time-consuming, and often confusing. Plus, funded scientists are finding it harder and harder to enroll participants in trials in a timely and cost-efficient way. Clinical Trials Connection helps make it easier for people with type 1 diabetes to take part in clinical trials, while addressing the difficulty researchers are having in finding trial participants.
Continuous glucose monitors are more than simply devices of convenience for people with diabetes—they are tools that can substantially improve blood sugar control when used regularly. The CGM study also underscores the importance of continued research into a closed-loop artificial pancreas, a device that uses CGM data to automatically administer appropriate doses of insulin through a pump.
Clinical trials are showing that improvements in blood sugar control can be gained using combinations of drugs that work together to regenerate insulin-producing beta cells. Industry partnerships will be pivotal to pushing these achievements even further and bringing benefits to type 1 patients.
A promising treatment called SB-509, for a form of diabetic neuropathy that affects nerve cells in the legs, is being evaluated in a Phase 2 clinical trial.